Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancersAnne Mc Leer, Matthieu Foll, Marie Brevet, et al.
Advances in Therapy|February 13, 2026
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French PatientsNicolas Girard, Pauline Macouillard, Danalyn Byng, et al.
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Frontiers in Oncology|March 7, 2025
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysisGrégoire Justeau, Christos Chouaid, Didier Debieuvre, et al.
Translational Oncology|September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trialGuénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2023
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trialGuénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, et al.
Clinical Lung Cancer|September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France StudyPierre Mordant, Solenn Brosseau, Bernard Milleron, et al.
Cancers|December 23, 2022
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP CohortsChristos Chouaid, Michael Thomas, Didier Debieuvre, et al.
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Pageof 9